Home > Healthcare > Medical Devices > Diagnostic Devices > Heart Failure POC and LOC Devices Market

Heart Failure POC and LOC Devices Market Share

Report ID: GMI9564
Published Date: May 2024
Report Format: PDF

Download Free Sample

Heart Failure POC and LOC Devices Market Share

The heart failure POC and LOC devices industry is highly competitive, marked by several players striving for market dominance. Providers offer comprehensive devices with improved efficiency and affordability. This includes advancements in reading, automation, data reporting, sensor design, and customization. Competition is driven by factors such as the quality, reliability, performance, cost, and compliance with regulatory standards. Strategic partnerships with companies and healthcare networks play a crucial role in market positioning.

Heart Failure POC and LOC Devices Market Companies

Some of the eminent market participants operating in the heart failure POC and LOC devices industry include:

Abaxis, Inc.
Abbott Laboratories
Becton, Dickinson and Company
bioMérieux S.A.
BioTelemetry, Inc.
Danaher Corporation
F. Hoffmann-La Roche Ltd.
Instrumentation Laboratory
Jant Pharmacal Corporation
Masimo Corporation
Novartis AG
Quidel Corporation
Siemens Healthineers AG
Stryker Corporation
Trinity Biotech

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Heart failure POC and LOC devices industry size was valued at USD 91.7 million in 2023 and is estimated to grow at 16.4% CAGR from 2024 to 2032, driven by advancements in diagnostic technologies.

The proteomic testing segment in the heart market is estimated to record USD 155.9 million by 2032, owing to its vitality in biomarker discovery and validation for heart failure and CVD.

U.S. heart failure POC and LOC devices market held a decent share in 2023 and is anticipated to grow at 16% CAGR during 2024-2032, owing to the significant burden of heart failure and CVD, with millions of individuals affected by these conditions.

Abaxis, Inc., Abbott Laboratories, Becton, Dickinson, and Company, bioM